GHRL rs696217: Understanding the Leu72Met Variant
The rs696217 variant is a single-nucleotide polymorphism located within the GHRL gene, which encodes the ghrelin-obestatin prepropeptide. This variant, often referred to as the Leu72Met substitution, has been studied for its potential associations with appetite regulation, satiety, and various metabolic traits.
What each genotype means
Typical ghrelin activity
This is the most common genotype for this variant. Some research suggests this genotype may be associated with higher scores in food approach traits, though findings across different populations are inconsistent and evidence remains limited.
This is the major genotype, carried by the majority of individuals in most global populations.
Varied appetite regulation profile
As a carrier of one copy of the variant allele, your ghrelin signaling may differ slightly from the common type. Studies have produced mixed results regarding its influence on eating behaviors, such as binge eating or satiety, and it is not a diagnostic indicator of any specific health outcome.
Carried by roughly 1 in 5 to 1 in 4 people of European ancestry, with varying frequencies in other global populations.
Potential altered satiety signaling
This genotype represents the homozygous variant state, sometimes referred to as the Met72Met variant. While some studies have explored associations with dairy consumption or specific eating patterns, the evidence is conflicting and not definitive; therefore, this result should not be used to predict personal health or dietary needs.
This is the least common genotype, typically found in a small percentage of the population depending on ancestral background.
What is rs696217?
The rs696217 variant is a specific genetic change, or single-nucleotide polymorphism (SNP), found within the GHRL gene. In genetic literature, this variant is frequently identified by the amino acid substitution it may cause, known as Leu72Met. This means that at position 72 of the protein sequence, the amino acid leucine is potentially replaced by methionine. The variant is located on chromosome 3 and is categorized as a trait-associated marker in various genomic databases. Because it sits within a gene responsible for producing key signaling peptides, researchers have long investigated whether this specific change alters the function or expression of the resulting proteins. It is important to note that while this SNP is well-documented in genomic catalogs, its functional impact remains a subject of ongoing scientific inquiry rather than a definitive cause of any specific health condition.
The Role of the GHRL Gene
The GHRL gene provides the instructions for creating the ghrelin-obestatin preproprotein. This precursor molecule is cleaved in the body to produce two distinct peptides: ghrelin and obestatin. Ghrelin is widely recognized as a powerful appetite stimulant that plays a critical role in energy homeostasis, hunger signaling, and the regulation of gastrointestinal motility. Conversely, obestatin was initially proposed to act as a satiety signal, though its exact physiological role remains a topic of active debate among researchers. Together, these products are involved in complex pathways that influence how the body perceives hunger, processes energy, and regulates metabolic functions. Because of its central role in these processes, the GHRL gene is frequently studied as a candidate for understanding variations in human eating behaviors and metabolic health.
Research and Evidence Strength
Research into the rs696217 variant has produced mixed results, leading to a classification of limited evidence regarding its clinical impact. While some studies have explored its association with body mass index (BMI), obesity, and eating behaviors, findings are often inconsistent across different populations. For instance, some investigations have looked for links between this variant and metabolic hormone levels, such as ghrelin or leptin, but have not always found statistically significant correlations. The complexity of appetite regulation, which involves numerous genes and environmental factors, makes it difficult to isolate the effect of a single SNP. Consequently, while rs696217 is a common subject in genetic association studies, it is not currently considered a reliable predictor for individual health outcomes or diagnostic purposes.
Population Frequency
The frequency of the rs696217 variant varies across different ancestral groups. In European populations, the minor allele frequency is typically observed to be between approximately 0.10 and 0.15. Because allele frequencies can differ significantly based on geographic and ethnic background, researchers must account for population structure when conducting association studies. This variation highlights the importance of studying diverse cohorts to understand how genetic markers like rs696217 are distributed globally. Data from large-scale projects, such as the genome Aggregation Database (gnomAD), provide essential insights into these frequencies, helping scientists contextualize the prevalence of the variant in various human populations.
Interpreting Genetic Information
It is important to understand that genetic variants like rs696217 represent only a small piece of a much larger biological puzzle. Because the evidence linking this variant to specific health traits is limited and often inconsistent, this information should not be used to make medical decisions or assumptions about personal health. Genetic associations observed in research studies describe trends across large groups of people and do not necessarily apply to any single individual. If you have questions about your metabolic health, weight management, or eating behaviors, the most appropriate course of action is to consult with a qualified healthcare provider or a registered dietitian. They can provide personalized guidance based on your overall health history, lifestyle, and clinical assessments, rather than relying on individual genetic markers.
How common is this variant?
The minor allele frequency for rs696217 is approximately 0.10 to 0.15 in European populations, though frequencies can vary across different global ancestries.
Frequently asked questions
Is rs696217 a cause of obesity?
No, rs696217 is not considered a direct cause of obesity. While it has been studied as a potential factor in appetite regulation, the evidence linking it to obesity is limited and inconsistent across different research studies.
Can I use this genetic information to change my diet?
Genetic information regarding this variant is not sufficient for creating a personalized diet plan. You should consult with a registered dietitian or healthcare provider to discuss nutrition and health goals based on your individual clinical needs.
What does the Leu72Met substitution do?
The Leu72Met substitution refers to a potential change in the amino acid sequence of the ghrelin-obestatin prepropeptide. Researchers investigate whether this change affects the function or processing of the protein, but its clinical significance remains unclear.
Where can I find more information about my own genetics?
If you have questions about your genetic profile, you should speak with a genetic counselor or your primary care physician. They can help you interpret genetic testing results in the context of your overall health.
Sources & further reading
Educational information only, last refreshed 10/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs696217?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29